Skip to main content
Offering brings in $2M for Delcath Systems

An offering of 2,360 shares of Series B preferred stock has pulled in $2 million for Delcath Systems, a company that is developing a system for delivering high dose chemotherapy to the liver. The proceeds will be used to support the company's general corporate functions.

Full Story: